Journal of clinical pharmacology, 52(5), 620-628 (2011-06-02)
Rasagiline is an irreversible monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of the signs and symptoms of idiopathic Parkinson disease as initial monotherapy and as adjunct therapy to levodopa. Pharmacologic inhibition of monoamine oxidase type A (MAO-A)
Responses of blood pressure and plasma catecholamines to intravenous injection of tyramine at increasing dosage (30, 45, and 60 microgram/kg, respectively) were evaluated in 25 normal subjects and 20 patients with mild essential hypertension. Basal plasma norepinephrine and epinephrine concentrations
The major side effect with the use of first generation of non selective monoamine oxidase (MAO) inhibitors as neuropsychiatric drugs was what became known as the "cheese reaction". Namely, potentiation of sympathomimetic activity of ingested tyramine present in cheese and
General and comparative endocrinology, 162(1), 18-26 (2008-07-01)
It is well acknowledged that tyramine acts as the biosynthetic intermediate precursor for octopamine. This fact has biased the interpretation of biological effects of tyramine towards an artifact of it being a partial agonist on octopamine receptors. Over recent years
Tyrosinase activity is monitored by pi-donor-acceptor force interactions between a bipyridinium-modified AFM tip and the biocatalytic reaction product generated on a tyramine- (or dopamine-) modified surface. Upon oxidation of the surface to dopaquinone as a result of tyrosinase activity, force
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
